

In the Claims:

- 1.-35. (cancelled)
36. (New) A pharmaceutical composition comprising a combination of a selective or specific COX 2 inhibitor or a pharmaceutically acceptable salt or derivative thereof, an opiate or a pharmaceutically acceptable salt or derivative thereof, and a centrally-acting cyclo-oxygenase inhibitor or a pharmaceutically acceptable salt or derivative thereof, as active ingredients, and a pharmaceutically acceptable carrier, wherein at least one of the active ingredients is provided in a sub-therapeutic amount.
37. (New) A pharmaceutical composition according to claim 36, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof.
38. (New) A pharmaceutical composition according to claim 36, wherein the opiate is selected from the group consisting of codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.
39. (New) A pharmaceutical composition according to claim 36, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.
40. (New) A pharmaceutical composition according to claim 36, wherein the selective or specific COX 2 inhibitor, opiate and centrally-acting cyclo-oxygenase inhibitor are provided in amounts such that the combination is therapeutically effective in treating pain, in an algesic and/or hyperalgesic state, with or without fever.

41. (New) A pharmaceutical composition according to claim 36, comprising a combination of meloxicam, or a pharmaceutically acceptable salt or derivative thereof, codeine, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
42. (New) A pharmaceutical composition according to claim 36, wherein the composition comprises a combination of meloxicam, or a pharmaceutically acceptable salt or derivative thereof, tramadol, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
43. (New) A pharmaceutical composition according to claim 36, consisting essentially of meloxicam, codeine and paracetamol.
44. (New) A pharmaceutical composition according to claim 36, wherein all of the active ingredients are provided in sub-therapeutic amounts.
45. (New) A combination of a selective or specific COX 2 inhibitor, an opiate and a centrally-acting cyclo-oxygenase inhibitor, or pharmaceutically acceptable derivatives or salts thereof, as active ingredients, for use in the treatment of pain, in an algesic and/or hyperalgesic state, with or without fever, wherein at least one of the active ingredients is provided in a sub-therapeutic amount, the amounts of the active ingredients being selected such that the combination is therapeutically effective.

46. (New) The combination of claim 45, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof
47. (New) The combination of claim 45, wherein all of the active ingredients are provided in sub-therapeutic amounts.
48. (New) The combination of claim 45, wherein the pain is associated with inflammation.
49. (New) The combination according to claim 48, wherein the pain is associated with trauma, osteoarthritis, rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea.
50. (New) The use of a combination of a selective or specific COX 2 inhibitor, an opiate and a centrally-acting cyclo-oxygenase inhibitor, or pharmaceutically acceptable salts or derivatives thereof, as active ingredients, in the manufacture of a medicament for use in a method of treating pain, in an algesic and/or hyperalgesic state, with or without fever, wherein at least one of the active ingredients is provided in a sub-therapeutic amount.
51. (New) The use of claim 50, wherein the medicament is provided in a dosage form selected from the group consisting of tablets, capsules, granules, suspensions, solutions and other liquid forms.

52. (New) The use of claim 51, wherein the medicament is administered orally, rectally, transdermally, intramuscularly or intravenously.
53. (New) The use of claim 52, wherein the dosage form is administered to a patient from 1 to 4 times a day.
54. (New) The use of claim 51, wherein the medicament is administered as an infusion, continuous or otherwise.
55. (New) A method of treating pain, in an algesic and/or hyperalgesic state, with or without fever, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a selective or specific COX 2 inhibitor, an opiate and a centrally-acting cyclo-oxygenase inhibitor, or pharmaceutically acceptable salts or derivatives thereof, as active ingredients, wherein at least one of the active ingredients is provided in a sub-therapeutic amount.
56. (New) A method according to claim 55, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof.
57. (New) A method according to claim 55, wherein the opiate is selected from the group comprising codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.

58. (New) A method according to claim 55, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.
59. (New) A method according to claim 55, comprising administering to a patient in need thereof a combination of meloxicam, codeine and paracetamol.
60. (New) A method according to claim 55, comprising administering to a patient in need thereof a combination of meloxicam, tramadol and paracetamol.
61. (New) A method according to claim 59, wherein the meloxicam is provided in an amount to give a daily dose from about 0.5 mg to about 30 mg.
62. (New) A method according to claim 59, wherein the daily dose of meloxicam is from about 7.5 mg to about 15 mg.
63. (New) A method according to claim 59, wherein the codeine is provided in an amount to give a daily dose from about 10 mg to about 360 mg.
64. (New) A method according to claim 60, wherein the tramadol is provided in an amount to give a daily dose from about 25 mg to about 500mg.
65. (New) A method according to claim 55, wherein the paracetamol is provided in an amount to give a daily dose from about 60 mg to about 4000 mg.

66. (New) A method according to claim 59, wherein the ratio of meloxicam to codeine is about 0.05 to 2.0 meloxicam: 1 to 6 codeine.
67. (New) A method according to claim 66, wherein the ratio of meloxicam to codeine is from about 0.1 to 1.0 meloxicam: 2 to 4 codeine.
68. (New) The combination of claim 45, wherein the opiate is selected from the group consisting of codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.
69. (New) The combination of claim 45, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.
70. (New) The combination of claim 45, wherein the selective or specific COX 2 inhibitor, opiate and centrally-acting cyclo-oxygenase inhibitor are provided in amounts such that the combination is therapeutically effective in treating pain, in an algescic and/or hyperalgescic state, with or without fever.
71. (New) The combination of claim 45, wherein the combination comprises meloxicam, or a pharmaceutically acceptable salt or derivative thereof, codeine, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
72. (New) The combination of claim 45, wherein the combination comprises meloxicam, or a pharmaceutically acceptable salt or derivative thereof, tramadol, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
73. (New) The combination of claim 45, wherein the combination consists essentially of meloxicam, codeine and paracetamol

74. (New) The combination of claim 45, wherein all of the active ingredients are provided in sub-therapeutic amounts
75. (New) A method according to claim 60, wherein the meloxicam is provided in an amount to give a daily dose from about 0.5 mg to about 30 mg.
76. (New) A method according to claim 60, wherein the daily dose of meloxicam is from about 7.5 mg to about 15 mg.